© Reuters. FILE PHOTO: An organization emblem is seen on the AstraZeneca website in Macclesfield, Britain, Could 11, 2021. REUTERS/Phil Noble/File Picture
(Reuters) -Drugmaker AstraZeneca (NASDAQ:) is drafting a plan to spin off its China enterprise, and itemizing a separate unit in Hong Kong is being seen as an choice, the Monetary Instances reported on Sunday.
A separation may not in the end happen, the report mentioned, citing individuals conversant in the matter, with one among them saying itemizing the entity in Shanghai was additionally potential.
The corporate would search to be a patriotic firm in China that “loves the Communist Occasion”, its China president mentioned in Could. Final yr, the nation accounted for 13% of AstraZeneca’s complete gross sales, and the corporate is China’s largest drugmaker.
The spin off may defend AstraZeneca from tensions between China and different international powers, whereas the corporate retained management of the enterprise, the FT’s report mentioned.
It added the concept has been round for years however was just lately sidelined by a worldwide biotech downturn.
AstraZeneca mentioned it didn’t touch upon “rumours or speculations round future technique or M&A.”
.jpeg?itok=EJhTOXAj'%20%20%20og_image:%20'https://cdn.mises.org/styles/social_media/s3/images/2025-03/AdobeStock_Supreme%20Court%20(2).jpeg?itok=EJhTOXAj)
